Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hiroto Konishi"'
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Various treatment options, such as molecular targeted drugs and immune checkpoint blockades, are available for patients with cancer. However, some cancer types are refractory to molecular targeted therapies or acquire drug resistance after l
Externí odkaz:
https://doaj.org/article/d20f4b05e2524f6089fb510d1e30c87c
Publikováno v:
Biochemical and biophysical research communications. 641
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs), such as osimertinib, show great success in non-small-cell lung cancer patients with EGFR mutated tumors. However, almost all patients develop resistance to EGFR-TKIs owing to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75dbce79630741dd8b40e884df46ad5
https://pubmed.ncbi.nlm.nih.gov/36527745
https://pubmed.ncbi.nlm.nih.gov/36527745
Autor:
Kazuma Higashisaka, Kazuya Nagano, Sachiyo Hanamuro, Hiroto Konishi, Yuya Haga, Lili Yang, Ying Lin, Hirofumi Tsujino, Yasuo Tsutsumi, Kohei Izusawa
Publikováno v:
Molecular Cancer Therapeutics. 18:B114-B114
To overcome the resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer, the mechanism clarification and novel molecular target development are urgently required. From this viewpoint, we previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb50d2cfd054e88cdc9b05729607301
https://doi.org/10.1158/1535-7163.targ-19-b114
https://doi.org/10.1158/1535-7163.targ-19-b114
Publikováno v:
The proceedings of the JSME annual meeting. :19-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7497eb02ea480fa1b6b0e7dd32cf5ce2
https://doi.org/10.1299/jsmemecjo.2008.2.0_19
https://doi.org/10.1299/jsmemecjo.2008.2.0_19